

AD HOC RELEASE

Changes in the BRAIN Management Board

Zwingenberg, September 23, 2016: The Supervisory Board of BRAIN AG (ISIN DE0005203947 / WKN 520394) today decided to appoint Frank Goebel, since February 2015 Managing Director of B.R.A.I.N. Capital GmbH, to the Management Board of BRAIN AG. This decision was taken upon a written request from COO Eric Marks, which he handed over to the Chairman of the Supervisory Board in advance of today's board meeting, and where he asked to end his mandate before its expiration in October 2018.

Taking this into account, the Supervisory Board has taken the following decisions in today's Supervisory Board meeting:

- 1) Frank Goebel will be appointed to the Executive Board of BRAIN AG, starting from November 1, 2016. He will take over the responsibility for the subsidiaries from Eric Marks. The CEO Dr. Juergen Eck will be responsible for the remaining tasks of Eric Marks.
- 2) Eric Marks will leave the Management Board as of October 31, 2016.
- 3) The Management Board appointment of Dr Georg Kellinghusen, which expires on December 31, 2016, has been extended until the end of the ordinary Annual General Meeting held in March 2017.

Contact:

B·R·A·I·N
Biotechnology Research
And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany

Tel.: +49-6251-9331-16
Fax: +49-6251-9331-11
E-Mail: ir@brain-biotech.de
www.brain-biotech.de



4) After the 2017 Annual General Meeting, Frank Goebel will additionally assume the CFO responsibilities of Dr Georg Kellinghusen. As from that date and until further notice, the BRAIN AG shall be led by a two-member Executive Board.

+++ENDS+++

About BRAIN

BRAIN is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. Today, BRAIN's business model is based on two pillars – "BioScience" and "BioIndustrial". The first pillar, "BioScience", comprises its – frequently exclusive – collaboration business with industrial partners. The second pillar "BioIndustrial" comprises the development and commercialisation of BRAIN's own products and active product components. Further information is available at www.brain-biotech.de/en